Barclays Maintains Equal-Weight on Biogen, Raises Price Target to $230
Benzinga Newsdesk 5 days ago
Analyst RatingsNewsPrice Target
Barclays analyst Emily Field maintains Biogen (NASDAQ:BIIB) with a Equal-Weight and raises the price target from $200 to $230.
Barclays analyst Emily Field maintains Biogen (NASDAQ:BIIB) with a Equal-Weight and raises the price target from $200 to $230.